question for bartm
Bartm, before you go back into hibernation (does anything hibernate in Australia?), you sound as if you were able to guage the mood at the recent conference.
Were the delegates pro, anti or neutral re gtg's position of control over intron analysis?
I'm medically qualified (and a degree in tumour biology), so understand genetic concepts and practise, but would be interested to hear a genetecists take on the matter.
I've just bought shares for long term.
GTG Price at posting:
0.0¢ Sentiment: LT Buy Disclosure: Held
